BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mazzaro C, Quartuccio L, Adinolfi LE, Roccatello D, Pozzato G, Nevola R, Tonizzo M, Gitto S, Andreone P, Gattei V. A Review on Extrahepatic Manifestations of Chronic Hepatitis C Virus Infection and the Impact of Direct-Acting Antiviral Therapy. Viruses 2021;13:2249. [PMID: 34835054 DOI: 10.3390/v13112249] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
Number Citing Articles
1 Coppola C, Kondili LA, Staiano L, Cammarota S, Citarella A, Aloisio MP, Annunziata A, Bernardi FF, D’avino A, D’orazio M, Fogliasecca M, Fusco M, Pisano F, Vercellone A, Bianco E, Trama U. Hepatitis C Virus Micro-Elimination Plan in Southern Italy: The “HCV ICEberg” Project. Pathogens 2023;12:195. [DOI: 10.3390/pathogens12020195] [Reference Citation Analysis]
2 Quartuccio L, Bortoluzzi A, Scirè CA, Marangoni A, Del Frate G, Treppo E, Castelnovo L, Saccardo F, Zani R, Candela M, Fraticelli P, Mazzaro C, Renoldi P, Scaini P, Filippini DA, Visentini M, Scarpato S, Giuggioli D, Mascia MT, Sebastiani M, Zignego AL, Lauletta G, Fiorilli M, Casato M, Ferri C, Pietrogrande M, Pioltelli PE, De Vita S, Monti G, Galli M. Management of mixed cryoglobulinemia with rituximab: evidence and consensus-based recommendations from the Italian Study Group of Cryoglobulinemia (GISC). Clin Rheumatol 2023;42:359-70. [PMID: 36169798 DOI: 10.1007/s10067-022-06391-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Nakagawa M, Asahina Y, Kakinuma S, Okamoto R. Impact of eradication of hepatitis C virus on liver-related and -unrelated diseases: morbidity and mortality of chronic hepatitis C after SVR. J Gastroenterol 2022. [PMID: 36585501 DOI: 10.1007/s00535-022-01940-1] [Reference Citation Analysis]
4 Weigand K, Peschel G, Grimm J, Müller M, Höring M, Krautbauer S, Liebisch G, Buechler C. HCV Infection and Liver Cirrhosis Are Associated with a Less-Favorable Serum Cholesteryl Ester Profile Which Improves through the Successful Treatment of HCV. Biomedicines 2022;10. [PMID: 36551908 DOI: 10.3390/biomedicines10123152] [Reference Citation Analysis]
5 Shehata GA, Ahmed GK, Hassan EA, Rehim ASEA, Mahmoud SZ, Masoud NA, Seifeldein GS, Hassan WA, Aboshaera KO. Impact of direct-acting antivirals on neuropsychiatric and neurocognitive dysfunction in chronic hepatitis C patients. Egypt J Neurol Psychiatry Neurosurg 2022;58:143. [DOI: 10.1186/s41983-022-00568-5] [Reference Citation Analysis]
6 Burgui C, San Miguel R, Goñi-esarte S, Juanbeltz R, Úriz-otano JI, Reparaz J, Sarobe M, Zozaya JM, Castilla J. Effectiveness of hepatitis C antiviral treatment and feasibility of hepatitis C elimination goal. Postgraduate Medicine 2022. [DOI: 10.1080/00325481.2022.2141499] [Reference Citation Analysis]
7 Yamataka K, Chu PS, Koda Y, Taniki N, Morikawa R, Yoshida A, Noguchi F, Kasuga R, Tabuchi T, Ebinuma H, Kanai T, Nakamoto N. Dynamics of type IV collagen 7S fragment on eradication of HCV with direct antiviral agents: Prognostic and metabolomic impacts. PLoS One 2022;17:e0276925. [PMID: 36301899 DOI: 10.1371/journal.pone.0276925] [Reference Citation Analysis]
8 Calleja Panero JL, de la Poza G, Hidalgo L, Aguilera Sancho-tello MV, Torras X, Santos de Lamadrid R, Maté C, Sánchez Antolín G. Patient journey of individuals tested for HCV in Spain: LiverTAI, a retrospective analysis of EHRs through natural language processing. Gastroenterología y Hepatología 2022. [DOI: 10.1016/j.gastrohep.2022.10.012] [Reference Citation Analysis]
9 Ramadan MS, Boccia F, Moretto SM, De Gregorio F, Gagliardi M, Iossa D, Durante-mangoni E, Zampino R. Cardiovascular Risk in Patients with Chronic Hepatitis C Treated with Direct Acting Antivirals. JCM 2022;11:5781. [DOI: 10.3390/jcm11195781] [Reference Citation Analysis]
10 Ghamar Talepoor A, Doroudchi M. Immunosenescence in atherosclerosis: A role for chronic viral infections. Front Immunol 2022;13:945016. [DOI: 10.3389/fimmu.2022.945016] [Reference Citation Analysis]
11 Dunaeva NV, Ulitina YI, Kolpashchikova EY, Romanova SY, Gusev DA. Analysis of mortality and risk of death in HCV- and HCV/HIV-infected patients with extrahepatic manifestations. jour 2022;14:87-95. [DOI: 10.22625/2072-6732-2022-14-2-87-95] [Reference Citation Analysis]
12 Salama II, Raslan HM, Abdel-Latif GA, Salama SI, Sami SM, Shaaban FA, Abdelmohsen AM, Fouad WA. Impact of direct-acting antiviral regimens on hepatic and extrahepatic manifestations of hepatitis C virus infection. World J Hepatol 2022; 14(6): 1053-1073 [DOI: 10.4254/wjh.v14.i6.1053] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Cheng T, Xu D, Yan Z, Ding C, Yang C, Zhang X. Antiviral Treatment for Hepatitis C Is Associated with a Reduced Risk of Periprosthetic Joint Infection: A Meta-analysis of Observational Studies. J Arthroplasty 2022:S0883-5403(22)00476-4. [PMID: 35483609 DOI: 10.1016/j.arth.2022.04.027] [Reference Citation Analysis]
14 Matsumori A. Novel Biomarkers of Inflammation for the Management of Diabetes: Immunoglobulin-Free Light Chains. Biomedicines 2022;10:666. [DOI: 10.3390/biomedicines10030666] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]